coumarin has been researched along with Local Neoplasm Recurrence in 3 studies
2H-chromen-2-one: coumarin derivative
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both coumarin (1,2-benzopyrone) and warfarin (4-hydroxycoumarin) have been shown to prevent the recurrence of malignant melanoma." | 9.07 | Treatment with coumarin to prevent or delay recurrence of malignant melanoma. ( Breslin, B; Browne, H; Browne, HY; Corrigan, T; Daly, L; Daly, P; Edwards, G; Gaffney, E; Lynch, G; Thornes, RD, 1994) |
| "Coumarin (1,2-benzopyrone) as a daily oral dose of 50 mg was evaluated in a multicentre prospectively randomized, double-blind, placebo-controlled trial to prevent early recurrence of malignant melanoma TNM Stage IB (Breslow thickness greater than 1." | 9.06 | Prevention of early recurrence of high risk malignant melanoma by coumarin. Irish Melanoma Group. ( Browne, H; Corrigan, T; Daly, L; Daly, P; Edwards, G; Keane, F; Lynch, G; O'Loughlin, S; Tanner, A; Thornes, D, 1989) |
| "Both coumarin (1,2-benzopyrone) and warfarin (4-hydroxycoumarin) have been shown to prevent the recurrence of malignant melanoma." | 5.07 | Treatment with coumarin to prevent or delay recurrence of malignant melanoma. ( Breslin, B; Browne, H; Browne, HY; Corrigan, T; Daly, L; Daly, P; Edwards, G; Gaffney, E; Lynch, G; Thornes, RD, 1994) |
| "Coumarin (1,2-benzopyrone) as a daily oral dose of 50 mg was evaluated in a multicentre prospectively randomized, double-blind, placebo-controlled trial to prevent early recurrence of malignant melanoma TNM Stage IB (Breslow thickness greater than 1." | 5.06 | Prevention of early recurrence of high risk malignant melanoma by coumarin. Irish Melanoma Group. ( Browne, H; Corrigan, T; Daly, L; Daly, P; Edwards, G; Keane, F; Lynch, G; O'Loughlin, S; Tanner, A; Thornes, D, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Draoui, N | 1 |
| Schicke, O | 1 |
| Seront, E | 1 |
| Bouzin, C | 1 |
| Sonveaux, P | 1 |
| Riant, O | 1 |
| Feron, O | 1 |
| Thornes, RD | 1 |
| Daly, L | 2 |
| Lynch, G | 2 |
| Breslin, B | 1 |
| Browne, H | 2 |
| Browne, HY | 1 |
| Corrigan, T | 2 |
| Daly, P | 2 |
| Edwards, G | 2 |
| Gaffney, E | 1 |
| Thornes, D | 1 |
| Tanner, A | 1 |
| Keane, F | 1 |
| O'Loughlin, S | 1 |
2 trials available for coumarin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Treatment with coumarin to prevent or delay recurrence of malignant melanoma.
Topics: Chemotherapy, Adjuvant; Coumarins; Double-Blind Method; Female; Humans; Life Tables; Male; Melanoma; | 1994 |
Prevention of early recurrence of high risk malignant melanoma by coumarin. Irish Melanoma Group.
Topics: Adult; Combined Modality Therapy; Coumarins; Female; Humans; Male; Melanoma; Middle Aged; Multicente | 1989 |
1 other study available for coumarin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux.
Topics: Animals; Breast Neoplasms; Colorectal Neoplasms; Coumarins; Female; HCT116 Cells; Humans; Lactic Aci | 2014 |